Nanobiotix annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Nanobiotix Stock-Based Compensation Growth & History (NANO)
Nanobiotix's stock-based compensation was €3.5M for fiscal 2025.
View full Nanobiotix company overviewNanobiotix annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €3.5M | −€759,000 | −17.66% |
| 2024 | 2024-12-31 | €4.3M | €1.1M | +33.40% |
| 2023 | 2023-12-31 | €3.2M | €48,000 | +1.51% |
| 2022 | 2022-12-31 | €3.2M | −€27,000 | −0.84% |
| 2021 | 2021-12-31 | €3.2M | €277,000 | +9.47% |
| 2020 | 2020-12-31 | €2.9M | −€1.4M | −32.31% |
| 2019 | 2019-12-31 | €4.3M | €2.5M | +131.39% |
| 2018 | 2018-12-31 | €1.9M | — | — |
Nanobiotix stock-based compensation trends
Over the last five fiscal years, Nanobiotix's stock-based compensation increased from €2.9M to €3.5M, a change of €615,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nanobiotix source filings ↗